Triptolide treatment reduces Alzheimer's disease (AD)-like pathology through inhibition of BACE1 in a transgenic mouse model of AD

• Main Authors: Qi Wang (Author), Bing Xiao (Author), Shuqin Cui (Author), Hailong Song (Author), Yanjing Qian (Author), Lin Dong (Author), Haiting An (Author), Yanqiu Cui (Author), Wenjing Zhang (Author), Yi He (Author), Jianliang Zhang (Author), Jian Yang (Author), Feilong Zhang (Author), Guanzheng Hu (Author), Xiaoli Gong (Author), Zhen Yan (Author), Yan Zheng (Author), Xiaomin Wang (Author)
• Format: Book
• Published: The Company of Biologists, 2014-12-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

The complex pathogenesis of Alzheimer's disease (AD) involves multiple contributing factors, including amyloid β (Aβ) peptide accumulation, inflammation and oxidative stress. Effective therapeutic strategies for AD are still urgently needed. Triptolide is the major active compound extracted fro...